Targeting of Escherichia coli with Vancomycin-Arginine.

The ability of vancomycin-arginine (V-r) to extend the spectrum of activity of glycopeptides to Gram-negative bacteria was investigated. Its MIC towards , including β-lactamase expressing Ambler classes A, B, and D, was 8 to 16 μg/ml. Addition of 8 times the MIC of V-r to was acutely bactericidal and associated with a low frequency of resistance (<2.32 × 10). , V-r markedly reduced burden by >7 log CFU/g in a thigh muscle model. These data warrant further development of V-r in combatting , including resistant forms.